Online Exclusives

Why Data Drives Drug Insights After Market

Liaison Technologies’ Gary Palgon discusses how to make sense of pharmacovigilance data to reveal meaningful insights

Related CONTENT

Kristin Brooks, Contract Pharma05.09.17

Despite the extensive research and development process for new medications, along with costly and lengthy clinical trials, it is crucial that prescription drugs continue to be monitored after they’ve been put on the market in order to study the effects of the drug and identify areas of improvement. Once pharmacovigilance data is collected, the real challenge is bringing it all together to make sense of it. Liaison Technologies’ vice president of Healthcare and Life Sciences Solutions, Gary Palgon, discusses how drug data can be used to reveal meaningful insights to better develop new drugs. –KB Contract Pharma: In what new ways is data being collected in drug development? Gary Palgon: Data is currency in the Information Age, and that model holds true in all industries, including pharma. Pharmaceutical companies need data to discover new products, enhance the patient experience and increase profits

Continue reading this story and get 24/7 access to Contract Pharma for FREE

FREE SUBSCRIPTION

Already a subscriber? Login

Related Searches

Suggested For You

The Future of Clinical Trials

Outsourcing the Manufacture of Clinical Trial APIs

Choosing and Managing a CDMO

Modularity in Injectables Manufacturing

Sai Life Sciences Opens New Biology Facility in Hyperbad, India

Stelis Biopharma Appoints Mark Womack as CEO

ImmunoGenesis Opens Research Lab, Adds Key Roles

Covectra Enhances ATLAS Serialization Platform for Repackaging

Drug Product Safety and Security

Idifarma Launches Accelerated Pathway for Complex Drugs

Driving Efficiencies in Today’s Complex Trials

CanSino Biologics Gets OGYÉI GMP Certificate for COVID Vax

Thermo Fisher, UCSF to Open Cell Therapy cGMP Mfg. Center

CDMO Market Trends & Opportunities

Exploring ICP-MS expertise at Almac

Related Columns

Clinical Trials

The Future of Clinical Trials

Dr. Greg Licholai of ICON plc on key market trends, the future of clinical trials and the acquisition of PRA.
Kristin Brooks, Managing Editor 09.09.21
APIs | Clinical Trial Materials

Outsourcing the Manufacture of Clinical Trial APIs

What to consider when deciding to partner with a CDMO for manufacturing.
Josh Hoerner, General Manager, Purisys 09.09.21
Choosing and Managing a CDMO

Speed up your time-to-market, keep development costs under control and smooth the FDA approval and commercial launch process.
Dana Toops, President, Avema Pharma Solutions 09.09.21
cGMP Manufacture | Fill/Finish | Parenterals

Modularity in Injectables Manufacturing

Raffaele Pace of Stevanato Group discusses injectable trends, challenges for manufacturers, and solutions for production customization.
Kristin Brooks, Managing Editor, Contract Pharma 08.19.21
Breaking News | Facilities | Industry News

Sai Life Sciences Opens New Biology Facility in Hyperbad, India

Positions itself as a differentiated player in Discovery Biology.
08.19.21